³Ô¹ÏºÚÁÏ

IMS Solutions is developing a world-first stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS), and a more accurate diagnostic for Adrenocortical Carcinoma (ACC).

Intelligent Mass Spec Solutions Ltd (IMS Solutions) is a new spinout launched by ³Ô¹ÏºÚÁÏ and the University of Birmingham that is set to revolutionise diagnosis of conditions featuring disordered steroid metabolism such as Polyendocrine Metabolic Ovarian Syndrome (PMOS).

IMS Solutions is launching with a strong commercial and scientific team, and a well-advanced roadmap for products that align with current demands from patients, clinicians and healthcare providers. Dr Martin Whitaker CEO, IMS Solutions

Steroid hormones orchestrate many of the body’s fundamental processes, including stress responses, metabolism, energy use, blood pressure regulation, reproduction and fertility.  Consequently, conditions where steroid hormone synthesis or metabolism are disrupted often present with diffuse and diverse symptoms, making them difficult, time-consuming and costly to diagnose. 

IMS Solutions’ platform technology overcomes this diagnostic challenge by detecting unique steroid signatures in urine and blood.

Funding

IMS Solutions launches with a £1.1 million Seed round led by Midlands Mindforge alongside a syndicate including SFC Capital, the UK’s Innovation and Seed Capital Fund (UKI2S - managed by Future Planet Capital), NG Bio, British Business Bank and private investors. The company is further supported by a £2.1 million grant from the NIHR awarded to ³Ô¹ÏºÚÁÏ under the Invention for Innovation programme.

The funding will enable the company to refine, advance and launch a urine test for the early diagnosis of the rare and difficult to treat cancer Adrenocortical Carcinoma (ACC) in the UK by 2029, and develop the world’s first stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS), the most common hormone disorder in women, which globally affects 10-15% of the female population. 

Dr Martin Whitaker, CEO of IMS Solutions said: “IMS Solutions is launching with a strong commercial and scientific team, and a well-advanced roadmap for products that align with current demands from patients, clinicians and healthcare providers.”

Foundation

IMS Solutions is a joint spinout from the University of Birmingham and ³Ô¹ÏºÚÁÏ, who have provided background patent and know-how intellectual property exclusively to the company.

The technology platform was initially developed at the University of Birmingham by Professor Wiebke Arlt, who is Chief Scientific Officer at IMS Solutions.  Professor Arlt, a renowned expert in steroid endocrinology, is Director of the (LMS), where she leads the Steroids & Metabolism research group, and Head of Department at the Institute of Clinical Sciences at ³Ô¹ÏºÚÁÏ. She also serves as the first female President of the European Society of Endocrinology.

Realising the opportunity

IMS Solutions says its first product to market will be a urine test that can discriminate between benign and malignant adrenal tumours, which are found in 5% of people undergoing a scan of the chest or abdomen. The ACCelerate™ test rapidly identifies patients requiring surgery for Adrenocortical Carcinoma (ACC) and reduces the need for surgery in patients whose adrenal tumours are eventually found to be benign.  

The NIHR Invention for Innovation (i4i) Product Development Award will support Professor Arlt’s ongoing research at the at ³Ô¹ÏºÚÁÏ’s Hammersmith Hospital Campus. The award will enable the regulatory certification and commercialisation of ACCelerate™, which consists of a unique panel of biomarkers and a machine learning algorithm trained on a retrospective data set to detect a malignant steroid fingerprint.  The algorithm has already been validated prospectively in a that showed the test is up to four times more accurate than scans alone.  

Professor Arlt said: “We validated the test through the largest ever adrenal cancer study, which involved over 2,000 patients from 11 countries, and this proved the test’s accuracy.  The funding means we can now optimise the test and certify to current regulatory standards. In addition, we intend to show that it is also good value for money and can be reliably performed in existing NHS laboratories, without new machines or additional costs.”

Unmet needs in PMOS  

We now know that PMOS is not a single disorder but that there are different PMOS subgroups, and some more than others increase the risk of metabolic diseases such as type 2 diabetes, hypertension and cardiovascular disease. Professor Wiebke Arlt Chief Scientific Officer, IMS Solutions

Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as PCOS or Polycystic Ovary Syndrome, affects much more than the ovaries.  It involves multiple hormones, affects how the body processes food and energy, and comes with a significantly raised risk of long-term health conditions such as type 2 diabetes, hypertension, and fatty liver disease. This complex picture is representative of the challenges in diagnosing and treating steroid hormone related conditions and their potential for poor patient outcomes, something IMS Solutions is working to solve.

Although 10-15% of women are affected by PMOS, according to the World Health Organization, up to 70% of these are undiagnosed.  There is no single test for PMOS.  Diagnosis relies on matching the patient’s combination of symptoms, laboratory findings, and imaging to a set of criteria (known as the Rotterdam criteria). 

The test in development by IMS Solutions is a combination of a blood test measuring biomarkers and a unique machine learning algorithm. The test is designed for use in primary care, to stratify PMOS patients for treatment and/or improved management of the condition. Following a successful proof-of-concept study a clinical validation study is in progress.  The results are expected to be announced shortly, and publication is anticipated in the next six months.

Professor Arlt said: “We now know that PMOS is not a single disorder but that there are different PMOS subgroups, and some more than others increase the risk of metabolic diseases such as type 2 diabetes, hypertension and cardiovascular disease. The test we are developing will be able to discern which category patients are in, and identify health risks for an individual patient, enabling earlier and improved treatment options.”